Healthcare Revenue Cycle · Healthcare & Life Sciences
Should you build or buy Denial Management Software?
Denial Management Software tracks and works insurance claim denials — categorizing root causes using ANSI CARC and RARC codes, routing denials to work queues by type, generating appeal letters, and surfacing analytics on denial patterns to help revenue cycle teams prevent future rejections.
The build-vs-buy decision for Denial Management Software turns on how far AI has made the denial prediction and categorization layer independently replicable, and whether your per-claim vendor pricing compounds against your denial volume to the point where internal analytics infrastructure is cheaper; the economics are moving and teams with claims data infrastructure are re-evaluating.
Build it, buy it, or bridge?
When building makes sense
The build case for denial management is better-documented than in most healthcare revenue cycle categories. Multiple revenue cycle teams have shipped ML-based denial predictors in production, and the accuracy on high-volume payer patterns is competitive with vendor tools trained on broader but less institution-specific datasets. ANSI CARC and RARC codes are universal — the same denial patterns recur industry-wide — so the analytical logic isn't encoding proprietary institutional knowledge that only a vendor can provide. LLM-assisted appeals drafting has also become a tractable internal capability. What makes a build credible is the combination of data infrastructure (a claims warehouse with enough history to train on), engineering capacity, and high enough denial volume to generate statistically useful training data by payer pattern. When per-claim pricing compounds against that volume, the economics shift noticeably in favor of internal tooling over a 3-year horizon.
When buying makes sense
Buying denial management software makes sense when you need fast deployment, strong payer-specific rules libraries, and a vendor relationship that helps with appeals escalation when needed. Vendors like Waystar and Experian Health built their value partly on clearinghouse connectivity and partly on accumulated payer-specific denial rules that took years to compile — that library has genuine utility for organizations that haven't been systematically cataloguing their own denial patterns. Buying also makes sense when the revenue cycle team is operationally focused and doesn't have data science capacity to build and maintain a prediction model. AI-native entrants like AKASA are also changing the vendor model toward outcome-based pricing, which reduces the compounding cost concern for high-volume organizations without requiring any internal development.
The desk read
Denial root-cause categorization runs on ANSI CARC and RARC codes that are universal across payers. The same denial patterns recur industry-wide, which means the analytical logic isn't encoding any proprietary institutional knowledge. Vendors like Waystar and Experian Health built their value on workflow tooling and clearinghouse connectivity, but the analytical layer is increasingly commoditized. AKASA and similar AI-native entrants have made the prediction and categorization functions clearly replicable.
The build case is documented in production. Multiple revenue cycle teams have shipped ML-based denial predictors and LLM-assisted appeals drafting using their own claims data, and the accuracy on high-volume payer patterns is competitive with vendor tools trained on broader but less institution-specific datasets. Buying earns its keep when you need a fast deployment, strong payer-specific rules libraries, and a vendor relationship for appeals escalation support. The economics start to diverge when per-claim pricing compounds against a high denial volume and your team has the data infrastructure to train on your own payer mix.
Frequently asked
What is Denial Management Software?
Denial Management Software tracks and works insurance claim denials — categorizing root causes using ANSI CARC and RARC codes, routing denials to work queues by type, generating appeal letters, and surfacing analytics on denial patterns to help revenue cycle teams prevent future rejections.
When does building Denial Management Software make sense?
Building makes sense for health systems with claims data infrastructure and high denial volume — ML-based denial prediction has been shipped in production by multiple independent teams, and the underlying logic uses universal ANSI codes that aren't proprietary to any vendor.
When does buying Denial Management Software make sense?
Buying makes sense when you need fast deployment with payer-specific rules libraries already included, or when AI-native outcome-based vendors like AKASA are available — getting denial prediction benefits without requiring internal data science capacity.
What are the main Denial Management Software vendors?
Representative vendors include Waystar (Denials), Experian Health (ClaimSource), Quadax, AKASA. B4 Pro scores the full set.